Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease.

New dual binding site acetylcholinesterase (AChE) inhibitors have been designed and synthesized as new potent drugs that may simultaneously alleviate cognitive deficits and behave as disease-modifying agents by inhibiting the beta-amyloid (A beta) peptide aggregation through binding to both catalytic and peripheral sites of the enzyme. Particularly, compounds 5 and 6 emerged as the most potent heterodimers reported so far, displaying IC50 values for AChE inhibition of 20 and 60 pM, respectively. More importantly, these dual AChE inhibitors inhibit the AChE-induced A beta peptide aggregation with IC50 values 1 order of magnitude lower than that of propidium, thus being the most potent derivatives with this activity reported up to date. We therefore conclude that these compounds are very promising disease-modifying agents for the treatment of Alzheimer's disease (AD).

[1]  Debomoy K Lahiri,et al.  Butyrylcholinesterase: An Important New Target in Alzheimer's Disease Therapy , 2002, International Psychogeriatrics.

[2]  H. Levine,et al.  Screening for pharmacologic inhibitors of amyloid fibril formation. , 1999, Methods in enzymology.

[3]  J. Sussman,et al.  Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. , 1999, Structure.

[4]  George Hsiao,et al.  Homodimeric tacrine congeners as acetylcholinesterase inhibitors. , 2002, Journal of medicinal chemistry.

[5]  S. Moore,et al.  The adhesion function on acetylcholinesterase is located at the peripheral anionic site. , 1999, Biochemical and biophysical research communications.

[6]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[7]  V. Andrisano,et al.  Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 3. Effect of replacing the inner polymethylene chain with cyclic moieties. , 2004, Journal of medicinal chemistry.

[8]  A. Cavalli,et al.  SAR of 9-amino-1,2,3,4-tetrahydroacridine-based acetylcholinesterase inhibitors: synthesis, enzyme inhibitory activity, QSAR, and structure-based CoMFA of tacrine analogues. , 2000, Journal of medicinal chemistry.

[9]  F. J. Luque,et al.  Predicting relative binding free energies of tacrine-huperzine A hybrids as inhibitors of acetylcholinesterase. , 1999, Journal of medicinal chemistry.

[10]  H. Soreq,et al.  Acetylcholinesterase — new roles for an old actor , 2001, Nature Reviews Neuroscience.

[11]  Synthesis and Biological Evaluation of Tacrine‐Thiadiazolidinone Hybrids as Dual Acetylcholinesterase Inhibitors , 2005, Archiv der Pharmazie.

[12]  P. Kollman,et al.  A well-behaved electrostatic potential-based method using charge restraints for deriving atomic char , 1993 .

[13]  K. Courtney,et al.  A new and rapid colorimetric determination of acetylcholinesterase activity. , 1961, Biochemical pharmacology.

[14]  H. Levine,et al.  Thioflavine T interaction with synthetic Alzheimer's disease β‐amyloid peptides: Detection of amyloid aggregation in solution , 1993, Protein science : a publication of the Protein Society.

[15]  K. Higuchi,et al.  Kinetic analysis of amyloid fibril polymerization in vitro. , 1991, Laboratory investigation; a journal of technical methods and pathology.

[16]  P. Kollman,et al.  A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules , 1995 .

[17]  F. J. Luque,et al.  3D structure of Torpedo californica acetylcholinesterase complexed with huprine X at 2.1 A resolution: kinetic and molecular dynamic correlates. , 2002, Biochemistry.

[18]  E. Giacobini.  Cholinesterases: New Roles in Brain Function and in Alzheimer's Disease , 2003, Neurochemical Research.

[19]  J. Baños,et al.  N-Benzylpiperidine derivatives of 1,2,4-thiadiazolidinone as new acetylcholinesterase inhibitors. , 2000, European journal of medicinal chemistry.

[20]  F. J. Luque,et al.  New tacrine-huperzine A hybrids (huprines): highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease. , 2000, Journal of medicinal chemistry.

[21]  I Silman,et al.  A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation. , 2001, Biochemistry.

[22]  Vincenza Andrisano,et al.  Rational approach to discover multipotent anti-Alzheimer drugs. , 2005, Journal of medicinal chemistry.

[23]  Dominic M. Walsh,et al.  Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease , 2004, Neuron.

[24]  F. J. Luque,et al.  Rational design of reversible acetylcholinesterase inhibitors. , 2002, Mini reviews in medicinal chemistry.

[25]  P. Carlier,et al.  Heterodimeric tacrine-based acetylcholinesterase inhibitors: investigating ligand-peripheral site interactions. , 1999, Journal of medicinal chemistry.

[26]  N. Inestrosa,et al.  Acetylcholinesterase is a senile plaque component that promotes assembly of amyloid beta-peptide into Alzheimer's filaments. , 1996, Molecular psychiatry.

[27]  N. Inestrosa,et al.  Molecular interactions of acetylcholinesterase with senile plaques , 1998, Journal of Physiology-Paris.

[28]  Ettore Novellino,et al.  Specific targeting of acetylcholinesterase and butyrylcholinesterase recognition sites. Rational design of novel, selective, and highly potent cholinesterase inhibitors. , 2003, Journal of medicinal chemistry.

[29]  A. Cavalli,et al.  3-(4-[[Benzyl(methyl)amino]methyl]phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy. , 2003, Journal of medicinal chemistry.

[30]  N. Inestrosa,et al.  Peripheral binding site is involved in the neurotrophic activity of acetylcholinesterase. , 1999, Neuroreport.

[31]  M. Jann,et al.  Rivastigmine, a New‐Generation Cholinesterase Inhibitor for the Treatment of Alzheimer's Disease , 2000, Pharmacotherapy.

[32]  C. Arruti,et al.  Evidence for a noncholinergic function of acetylcholinesterase during development of chicken retina as shown by fasciculin , 2000, Cell and Tissue Research.

[33]  N. Cutler,et al.  Galantamine hydrobromide: an agent for Alzheimer's disease. , 2003, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[34]  D. Selkoe.  Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[35]  H. Sugimoto.  Donepezil hydrochloride: a treatment drug for Alzheimer's disease. , 2001, Chemical record.

[36]  S. Kaldor,et al.  Solid phase synthesis of hydantoins using a carbamate linker and a novel cyclization / cleavage step , 1996 .

[37]  Hans-Dieter Höltje,et al.  Structure-based 3D-QSAR—merging the accuracy of structure-based alignments with the computational efficiency of ligand-based methods , 2000 .

[38]  V. Andrisano,et al.  beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. , 2003, Biochemical pharmacology.

[39]  S. Brimijoin,et al.  Direct evidence for an adhesive function in the noncholinergic role of acetylcholinesterase in neurite outgrowth , 2001, Journal of neuroscience research.

[40]  A. Goldman,et al.  Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein , 1991, Science.